Elevance's insurance segment earned $436 million in the third quarter, down from $601 million a year ago (Elevance Health Q3 2026 release, October 2026). Its operating margin was 1.0%. Elevance reported the quarter on October 21 as a beat and raised its outlook, because net investment income rose $412 million.
Adjusted diluted EPS came in at $6.99, up 15.9%, and full-year guidance moved to at least $29.00 (Elevance, October 2026). Pre-tax income rose 27.6% while the operating gain across all segments fell 2.0%. Its release also describes a "net non-operating benefit of $1.85 per share" in the quarter. Two numbers an actuary reads first, the benefit expense ratio and days in claims payable, moved in a way that needs the reserve table to interpret.
Key Takeaways
- Profit in the insurance segment fell by more than a quarter: Health Benefits operating gain of $436 million, a 1.0% margin.
- Investment income carried the beat: net investment income of $1,037 million, up 65.9% from $625 million.
- The benefit expense ratio improved 70 basis points to 90.6% while days in claims payable rose 3.5 days to 44.9.
- Claims are being paid more slowly: current-year claims paid as a share of incurred fell to 85.1% from 86.3%.
- Medicare Advantage is a much smaller book: membership of 1.9 million, down 15.5% in a year.
What Moved Between the Segment Line and the Bottom Line
Operating revenue was $50.4 billion, up 0.7%. Health Benefits revenue grew 2.6% to $43.4 billion on higher premium yields, with fewer members in Medicare Advantage, Medicaid and employer risk business. Carelon, the services and pharmacy arm, earned $0.9 billion, up 17% (Elevance, October 2026). Reportable segments together produced an operating gain of $1,269 million, against $1,295 million a year ago.
Below the segment line, net investment income rose to $1,037 million from $625 million. Income before tax rose to $1,794 million from $1,406 million. All of that $388 million increase, and more, is the investment line. Share repurchases cut the diluted count 2.7%, which lifts the per-share figure further.
| Item (in millions except per share) | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Health Benefits operating gain | $436 | $601 | -27.5% |
| Carelon operating gain (Rx plus Services) | $908 | $775 | +17.2% |
| Reportable segments operating gain | $1,269 | $1,295 | -2.0% |
| Net investment income | $1,037 | $625 | +65.9% |
| Income before income tax | $1,794 | $1,406 | +27.6% |
| Adjusted diluted EPS | $6.99 | $6.03 | +15.9% |
Guidance carries the same split. Elevance guides to at least $29.00 of adjusted EPS for 2026 and to at least 12% growth in 2027 from "a higher earnings baseline of at least $26.75" (Elevance, October 2026). A footnote defines the baseline as excluding non-recurring net investment income, other non-operating items and one-time investments. Twelve percent on $26.75 is about $30, roughly 3% above this year's guided figure. So the growth rate is measured from a base that strips out $2.25 of what 2026 earned.
The Benefit Ratio and the Claims Payable Build
Elevance's benefit expense ratio improved to 90.6% from 91.3%. Elevance credits "better performance in Medicare Advantage and Individual ACA compared to the prior year" (Elevance, October 2026). In the same paragraph, days in claims payable stood at 44.9, up 3.5 days year over year. Medical claims payable on the balance sheet reached $18,438 million, from $17,084 million at year-end.
A reserve roll-forward explains how both can be true. For the nine months, current-year claims paid as a percentage of current-year incurred claims were 85.1%, down from 86.3% (Elevance, October 2026). Prior-year redundancies were $1,295 million against $1,266 million a year earlier, 0.9% of prior-year incurred claims against 1.0%. Incurred claims that set the ratio therefore carry a larger unpaid share than last year's did, and last year's unpaid share released at the usual rate.
That combination allows two readings. If the added reserve is conservative, it releases in 2027 and the true 2026 ratio is lower than 90.6%. If payment patterns have slowed because claims are arriving later, the ratio is right and the reserve is catching up to a later-developing book. Nothing in the roll-forward separates the two until the 2026 accident year ages. Elevance's reported redundancy ratio, prior-year releases as a share of prior-year payable, has fallen from 12.3% in 2024 to 8.4% now, so the cushion from earlier years is thinner than it was.
Membership frames the Medicare Advantage credit. Elevance served 1,898 thousand Medicare Advantage members at September 30, down 15.5% from 2,245 thousand (Elevance, October 2026). Medicaid membership fell 4.9% while Medicaid revenue rose 5.7% to $14,979 million, so premium per member rose about 11% on the site's arithmetic. Employer risk membership fell 6.9%. Books that improved are books that shrank.
Two peers reported the same week from different positions. UnitedHealth's medical care ratio of 88.4% included $610 million of favorable development on 2026 dates of service, with days claims payable at 47.0 (UnitedHealth Group, October 2026). Molina's consolidated ratio was 92.9%, and its nine-month prior-year development was $352 million against $124 million a year earlier (Molina Healthcare, October 2026). Elevance's ratio sits between them, built on a reserve that grew rather than one that was drawn.
The $935 Million Accrual Under the Baseline
One item in the nine-month reconciliation has not moved since June. An "accrual related to CMS notice" of $935 million, $4.28 per share, is "the Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustment data" tied to a CMS notice dated February 27, 2026 (Elevance, October 2026). It sits in Corporate & Other, outside the Health Benefits margin, and outside adjusted EPS.
That accrual is why the nine-month reportable segments operating gain reads $5,118 million, down 25.7%, while adjusted operating gain reads $6,359 million, down 10.3%. The site's Q2 managed-care piece read the two carriers' benefit ratios, which the accrual, booked outside the Health Benefits segment, did not touch. This quarter added nothing to it. A best estimate of a regulatory exposure is a reserve, and reserves of that kind move on new information from the regulator.
A $26.75 baseline excludes non-recurring investment income and one-time items. It does not describe what happens to the estimate if CMS extrapolates further. So the 2027 growth target is built on a base scrubbed of the items that helped 2026, with the one item that could still hurt held at a figure the company itself calls an estimate. Meanwhile the segment the target depends on earned 1.0% on revenue this quarter, on a Medicare Advantage book 15.5% smaller than the one that produced last year's comparison.
Further Reading
- UnitedHealth and Elevance Split the Q2 2026 Managed-Care Recovery: the second-quarter ratios this quarter's reserve build changes.
- UnitedHealth Cuts Its Expense Ratio 70 bps as the AI Gains It Quantifies Stay in Clinician Workflow: the peer quarter with $610M of favorable development.
- Molina's 92.7% Medicaid MLR and a Trough Call the Acuity Math Hasn't Confirmed: the Medicaid acuity question that Elevance's shrinking book raises again.
- Aetna's 250bp MBR Drop Rode a $471M Reserve Reversal: how a ratio improvement can be a reserve movement at another carrier.
- Elevance Sues CMS Over $115M in Medicare Advantage Star Ratings: the earlier dispute with the same regulator.